Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM0VBU)

• Drug Name: BCA101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMM0VBU

Molecule-Related Drug Atlas

Drug(s) Targeting Transforming growth factor beta (TGFB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M7824	DMJCULI	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[2]
Bintrafusp alfa	DMB9LRJ	Non-small-cell lung cancer	2C25	Phase 2	[3]
NIS793	DM8LBYT	Pancreatic ductal carcinoma	2C10.0	Phase 2	[2]
LY2382770	DMH3YKJ	Diabetic kidney disease	GB61.Z	Phase 2	[4]
Fresolimumab	DMFZ084	Brain cancer	2A00	Phase 2	[5]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
ACE-011	DMJ36YH	Anemia	3A00-3A9Z	Phase 1	[7]
AVID200	DMZ39T6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
RG6440	DMVQXFH	Aggressive cancer	2A00-2F9Z	Phase 1	[9]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[10]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[11]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[12]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[13]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[14]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[15]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[16]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[17]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[15]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[1]
Transforming growth factor beta (TGFB)	TTO3HT7	NOUNIPROTAC	Inhibitor	[1]

References

• [1] ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
• [4] A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
• [5] Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
• [6] Clinical pipeline report, company report or official report of Agenus.
• [7] Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
• [8] TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
• [9] Clinical pipeline report, company report or official report of Roche
• [10] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [11] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [12] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [13] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [14] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [16] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [17] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [18] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).